1-(4-Amino-2-methylbutan-2-yl)oxy-2-methylpropan-2-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-Amino-2-methylbutan-2-yl)oxy-2-methylpropan-2-ol
• 英文别名: 1-(4-amino-2-methylbutan-2-yl)oxy-2-methylpropan-2-ol
• 化学式: C₉H₂₁NO₂
• 分子量: 175.27
• InChiKey: GXQWMNVXEZPEQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Methylphenidate-prodrugs, processes of making and using the same
  申请人：KemPharm, Inc.

  公开号：US10231960B2

  公开（公告）日：2019-03-19

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  本技术涉及用于治疗各种疾病和/或失调的原药和组合物，包括与至少一种醇、胺、氧代酸、硫醇或其衍生物共轭的哌醋甲酯或哌醋甲酯衍生物。在某些实施方案中，共轭物还包括至少一种连接剂。本技术还涉及与至少一种醇、胺、氧代酸、硫醇或其衍生物或其组合共轭的哌醋甲酯或哌醋甲酯衍生物的合成。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20170049765A1

  公开（公告）日：2017-02-23

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
• ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO
  申请人：LegoChem Biosciences, Inc.

  公开号：US20220218840A1

  公开（公告）日：2022-07-14

  The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.
• US9676871B2
  申请人：——

  公开号：US9676871B2

  公开（公告）日：2017-06-13